9/11 Breast Cancer Claims: VCF Compensation & WTC Health Program Benefits

Who qualifies for 9/11 breast cancer compensation?

Anyone diagnosed with breast cancer following presence in the covered 9/11 areas, at the Pentagon, or in Shanksville, Pennsylvania during the covered periods may qualify for VCF compensation. This includes area workers, residents, students, teachers, first responders, cleanup and recovery workers, volunteers, and surviving family members of those who died from 9/11-related breast cancer.

Free medical care runs through the WTC Health Program, which covers Manhattan south of Houston Street and any block in Brooklyn within 1.5 miles of the former World Trade Center site. Compensation runs through the VCF, which covers Manhattan south of Canal Street plus routes of debris removal.

If you were between Canal and Houston Street, you may still qualify for both. Daily life in Lower Manhattan rarely stopped at Canal Street, and presence can be established with records or sworn affidavits.

Female breast cancer certifications rose sharply in the years following 9/11 as latency windows passed for exposed women who lived, worked, or attended school in Lower Manhattan. Male breast cancer, while rare in the general population, is also documented in the 9/11 community and is covered under the WTCHP's rare-cancer framework.

What types of breast cancer are covered by the WTC Health Program?

The WTC Health Program certifies invasive malignant neoplasms of the female breast and, as a rare cancer, invasive malignant neoplasms of the male breast. Coverage includes the most common invasive breast cancer subtypes.

• Invasive ductal carcinoma (IDC) — the most common type of breast cancer, accounting for approximately 80% of all diagnoses per American Cancer Society reference data. Begins in the milk ducts and invades surrounding breast tissue.
• Invasive lobular carcinoma (ILC) — a common invasive type per American Cancer Society reference data, arising from the lobules that produce milk.
• Inflammatory breast cancer — a rare and aggressive form that presents as redness, swelling, or skin changes rather than a discrete lump.
• HER2-positive, hormone receptor-positive, and triple-negative subtypes — all covered based on the underlying invasive diagnosis, though they inform treatment path and prognosis.
• Male breast cancer — covered under the WTCHP's rare-cancer framework as a malignant neoplasm of the male breast.

Non-invasive breast conditions, including ductal carcinoma in situ (DCIS), are evaluated case-by-case under the WTC Health Program's malignancy classification framework. Per the WTC Health Program Administrative Manual's Special Note on Malignancy for Cancers, non-invasive neoplasms including carcinomas in situ may qualify as certifiable malignant neoplasms if characterized histologically as malignant and regarded in peer-reviewed literature as having an increased risk of developing into invasive neoplasm, with reference to NCCN Guidelines.

Lobular carcinoma in situ (LCIS), except pleomorphic LCIS, is specifically listed in the Administrative Manual as ineligible. DCIS is not categorically ineligible; its certifiability depends on the case-by-case histologic and peer-reviewed evidence analysis under the Manual's framework. For the specific rules on in situ conditions, see our Covered Conditions reference page.

More than 400,000 people are estimated to have been exposed to 9/11 toxins in Lower Manhattan alone, with additional exposures at the Pentagon and Shanksville, Pennsylvania. The dust, smoke, and debris released by the collapse of the World Trade Center contained known and suspected carcinogens including asbestos, silica, polycyclic aromatic hydrocarbons, dioxins, furans, heavy metals, and endocrine-disrupting compounds. Downtown residents and workers, students, first responders, cleanup crews, and volunteers each experienced different exposure patterns, but all encountered the same underlying toxin mixture.

Several of the chemicals identified in the 9/11 dust have been linked in medical literature to breast tissue carcinogenesis, particularly through endocrine disruption and inflammatory mechanisms. Breast cancer certifications in the 9/11 community began rising several years after 2001 as the four-year latency window passed for exposed claimants.

Breast cancer does not appear immediately after exposure to a carcinogen. There is typically a period of years between exposure and clinical detection. The WTC Health Program requires a minimum four-year latency period between first 9/11 exposure and first breast cancer diagnosis before certification.

Certification does not require proof that 9/11 exposure was the only cause of a particular breast cancer. Under federal law, the standard is whether the exposure was substantially likely to be a significant factor in aggravating, contributing to, or causing the condition. Family history, BRCA1 and BRCA2 mutations, hormone replacement therapy use, and other established breast cancer risk factors generally do not prevent certification.

Breast cancer symptoms vary by subtype and by stage at detection. The checklist below covers the most common presentations. Any new or unusual breast change should be evaluated by a WTC Health Program participating physician.

• A new lump or mass in the breast or underarm, hard or painless being common but not universal
• Swelling of all or part of the breast, even without a distinct lump
• Skin dimpling, thickening, or a pitted appearance like an orange peel
• Breast or nipple pain of new onset
• Nipple retraction (turning inward) or change in nipple direction
• Nipple discharge other than breast milk, particularly if bloody
• Redness, scaliness, or thickening of the nipple or breast skin (potential inflammatory breast cancer sign)
• A lump or swelling in the underarm lymph nodes

Breast cancer symptoms in men present similarly, most often as a firm painless lump beneath the nipple, nipple retraction, or skin changes. Male breast cancer is less common than female breast cancer but should be evaluated with the same seriousness. Both female and male breast cancer are covered by the WTCHP when the four-year latency and other certification requirements are met.

The WTC Health Program requires a minimum four-year latency period between first 9/11 exposure and first breast cancer diagnosis. This latency requirement is set by the WTC Health Program and has no exceptions. A breast cancer diagnosed less than four years after first exposure cannot be certified as 9/11-related.

Most breast cancer claimants meet the four-year requirement on its face. First 9/11 exposure occurred in September 2001 or in the weeks and months following, so most breast cancers diagnosed from September 2005 forward satisfy latency depending on the first day of 9/11 toxin exposure. Diagnoses from 2010, 2015, or 2020 are all well past the latency threshold.

The two-year VCF registration deadline runs from the date the WTC Health Program certifies the breast cancer as 9/11-related, not from the date of diagnosis. Registration preserves the right to file a claim; the actual claim filing deadline is October 1, 2090 for all claimants. A breast cancer diagnosed years ago remains eligible for certification.

What is the VCF payout for 9/11 breast cancer?

Certified 9/11 breast cancer qualifies claimants for free medical treatment through the WTC Health Program, and allows the claimant to submit a claim for financial compensation through the September 11th Victim Compensation Fund. The VCF's non-economic loss award for breast cancer is published in its Non-Economic Loss Awards and Certified Conditions Fact Sheet.

Non-economic loss award range for breast cancer

• Female breast cancer: non-economic loss awards usually receive the statutory maximum, $250,000, for a single cancer condition.
• Male breast cancer: covered under the WTCHP's rare-cancer framework and also eligible for VCF compensation at the $250,000 statutory maximum.

Aggregate compensation with multiple certified conditions

Non-economic loss compensation for a single cancer condition is capped at $250,000 under the VCF Act. Where a claimant has multiple certified conditions on their own record (for example, breast cancer plus another certified cancer or a certified respiratory condition), aggregate non-economic loss may reach the current VCF maximum of $340,000. Aggregate compensation is determined based on the severity of each certified condition, not simply by adding baseline amounts.

Economic loss and wrongful death compensation

In addition to non-economic loss, the VCF may award economic loss for medical expenses, lost earnings, and other financial impacts from breast cancer treatment. These economic loss awards can be substantial in cases involving extended treatment, complications from chemotherapy or radiation, mastectomy and reconstruction, or ongoing surveillance. Wrongful death compensation is available to the personal representatives of individuals who died from 9/11-related breast cancer. Attorney fees for VCF claims are capped at 10% by federal statute.

How Baione Law handles a 9/11 breast cancer claim

Baione Law represents 9/11 breast cancer claimants at every stage:

1. Free Case Review. The firm evaluates presence in the exposure zone, exposure category, breast cancer diagnosis and subtype, and current WTCHP certification status. No cost, no obligation.
2. WTC Health Program enrollment and certification support. For claimants not yet enrolled, the firm assists with enrollment and coordinates medical record submission to WTCHP medical providers for certification, including for rare male breast cancer diagnoses.
3. VCF registration and claim filing. The firm registers the claim, files the compensation claim, and prepares supporting documentation including presence, exposure, pathology, staging, subtype, and treatment history.
4. Medical records and impact documentation. The firm compiles the medical, economic, and non-economic loss documentation the VCF requires, particularly relevant for breast cancer cases involving extended treatment, reconstruction, or long-term complications.
5. Award, appeals, and amendments. After the VCF issues an award, the firm reviews it, files an appeal if warranted, and handles amendments for subsequent certified conditions including any progression to metastatic disease.

Attorney fees are capped at 10% by federal statute.